Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell.

Yao WQ, Wu F, Zhang W, Chuang SS, Thompson JS, Chen Z, Zhang SW, Clipson A, Wang M, Liu H, Bibawi H, Huang Y, Campos L, Grant JW, Wright P, Ei-Daly H, Rásó-Barnett L, Farkas L, Follows GA, Gao Z, Attygalle AD, Ashton-Key M, Liu W, Du MQ.

J Pathol. 2020 Mar;250(3):346-357. doi: 10.1002/path.5376. Epub 2020 Jan 16.

2.

Cryptic insertions of the immunoglobulin light chain enhancer region near CCND1 in t(11;14)-negative mantle cell lymphoma.

Fuster C, Martín-Garcia D, Balagué O, Navarro A, Nadeu F, Costa D, Prieto M, Salaverria I, Espinet B, Rivas-Delgado A, Terol MJ, Giné E, Forcada P, Ashton-Key M, Puente XS, Swerdlow SH, Beà S, Campo E.

Haematologica. 2019 Nov 21. pii: haematol.2019.237073. doi: 10.3324/haematol.2019.237073. [Epub ahead of print] No abstract available.

3.

BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia.

Smith LD, Minton AR, Blunt MD, Karydis LI, Dutton DA, Rogers-Broadway KR, Dobson R, Liu R, Norster F, Hogg E, Ashton-Key M, Strefford JC, Jia L, Efremov DG, Helgason GV, Johnson PWM, Stevenson FK, Forconi F, Cragg MS, Tumbarello DA, Packham G, Steele AJ.

Leukemia. 2020 Feb;34(2):640-644. doi: 10.1038/s41375-019-0557-y. Epub 2019 Aug 28. No abstract available.

4.

Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression.

Roghanian A, Hu G, Fraser C, Singh M, Foxall RB, Meyer MJ, Lees E, Huet H, Glennie MJ, Beers SA, Lim SH, Ashton-Key M, Thirdborough SM, Cragg MS, Chen J.

Cancer Immunol Res. 2019 Nov;7(11):1876-1890. doi: 10.1158/2326-6066.CIR-18-0835. Epub 2019 Aug 26.

PMID:
31451483
5.

Role of feasibility and pilot studies in randomised controlled trials: a cross-sectional study.

Blatch-Jones AJ, Pek W, Kirkpatrick E, Ashton-Key M.

BMJ Open. 2018 Sep 25;8(9):e022233. doi: 10.1136/bmjopen-2018-022233.

6.

Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant.

Araf S, Wang J, Ashton-Key M, Korfi K, Di Bella D, Rio-Machin A, Odabashian M, Foria V, Du MQ, Cucco F, Barrans S, Johnson P, Laird SR, Fisher AM, Cullis JO, Graham TA, Okosun J, Fitzgibbon J, Chiecchio L.

Haematologica. 2019 Apr;104(4):e174-e177. doi: 10.3324/haematol.2018.196907. Epub 2018 Jul 5. No abstract available.

7.

Novel GPR34 and CCR6 mutation and distinct genetic profiles in MALT lymphomas of different sites.

Moody S, Thompson JS, Chuang SS, Liu H, Raderer M, Vassiliou G, Wlodarska I, Wu F, Cogliatti S, Robson A, Ashton-Key M, Bi Y, Goodlad J, Du MQ.

Haematologica. 2018 Aug;103(8):1329-1336. doi: 10.3324/haematol.2018.191601. Epub 2018 Apr 19.

8.

Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma.

Moody S, Escudero-Ibarz L, Wang M, Clipson A, Ochoa Ruiz E, Dunn-Walters D, Xue X, Zeng N, Robson A, Chuang SS, Cogliatti S, Liu H, Goodlad J, Ashton-Key M, Raderer M, Bi Y, Du MQ.

J Pathol. 2017 Sep;243(1):3-8. doi: 10.1002/path.4933. Epub 2017 Aug 7.

PMID:
28682481
9.

Recurrent constrictive pericarditis associated with seropositive rheumatoid arthritis: A case report.

Votano D, Tsang GM, Ashton-Key M, Göbölös L.

Int J Surg Case Rep. 2017;34:93-95. doi: 10.1016/j.ijscr.2017.03.027. Epub 2017 Mar 21.

10.

Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling.

Wang M, Zhang S, Chuang SS, Ashton-Key M, Ochoa E, Bolli N, Vassiliou G, Gao Z, Du MQ.

Oncotarget. 2017 Mar 14;8(11):17763-17770. doi: 10.18632/oncotarget.14846.

11.

Precision treatment with sirolimus in a case of activated phosphoinositide 3-kinase δ syndrome.

Rae W, Ramakrishnan KA, Gao Y, Ashton-Key M, Pengelly RJ, Patel SV, Ennis S, Williams AP, Faust SN.

Clin Immunol. 2016 Oct;171:38-40. doi: 10.1016/j.clim.2016.07.017. Epub 2016 Jul 19. No abstract available.

PMID:
27444043
12.

A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells.

Papadakis E, Robson N, Yeomans A, Bailey S, Laversin S, Beers S, Sayan AE, Ashton-Key M, Schwaiger S, Stuppner H, Troppmair J, Packham G, Cutress R.

Oncotarget. 2016 Apr 5;7(14):18851-64. doi: 10.18632/oncotarget.7944.

13.

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors.

Tutt AL, James S, Laversin SA, Tipton TR, Ashton-Key M, French RR, Hussain K, Vaughan AT, Dou L, Earley A, Dahal LN, Lu C, Dunscombe M, Chan HT, Penfold CA, Kim JH, Potter EA, Mockridge CI, Roghanian A, Oldham RJ, Cox KL, Lim SH, Teige I, Frendéus B, Glennie MJ, Beers SA, Cragg MS.

J Immunol. 2015 Dec 1;195(11):5503-16. doi: 10.4049/jimmunol.1402988. Epub 2015 Oct 28.

14.

Annexin A3 is a mammary marker and a potential neoplastic breast cell therapeutic target.

Zeidan B, Jackson TR, Larkin SE, Cutress RI, Coulton GR, Ashton-Key M, Murray N, Packham G, Gorgoulis V, Garbis SD, Townsend PA.

Oncotarget. 2015 Aug 28;6(25):21421-7.

15.

Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.

Parry M, Rose-Zerilli MJ, Ljungström V, Gibson J, Wang J, Walewska R, Parker H, Parker A, Davis Z, Gardiner A, McIver-Brown N, Kalpadakis C, Xochelli A, Anagnostopoulos A, Fazi C, de Castro DG, Dearden C, Pratt G, Rosenquist R, Ashton-Key M, Forconi F, Collins A, Ghia P, Matutes E, Pangalis G, Stamatopoulos K, Oscier D, Strefford JC.

Clin Cancer Res. 2015 Sep 15;21(18):4174-4183. doi: 10.1158/1078-0432.CCR-14-2759. Epub 2015 Mar 16.

16.

Lymph node granulomas in immunoglobulin G4-related disease.

Bateman AC, Ashton-Key MR, Jogai S.

Histopathology. 2015 Oct;67(4):557-61. doi: 10.1111/his.12658. Epub 2015 Mar 5.

PMID:
25620085
17.

Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study.

Johnson P, Challis R, Chowdhury F, Gao Y, Harvey M, Geldart T, Kerr P, Chan C, Smith A, Steven N, Edwards C, Ashton-Key M, Hodges E, Tutt A, Ottensmeier C, Glennie M, Williams A.

Clin Cancer Res. 2015 Mar 15;21(6):1321-8. doi: 10.1158/1078-0432.CCR-14-2355. Epub 2015 Jan 14.

18.

KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.

Clipson A, Wang M, de Leval L, Ashton-Key M, Wotherspoon A, Vassiliou G, Bolli N, Grove C, Moody S, Escudero-Ibarz L, Gundem G, Brugger K, Xue X, Mi E, Bench A, Scott M, Liu H, Follows G, Robles EF, Martinez-Climent JA, Oscier D, Watkins AJ, Du MQ.

Leukemia. 2015 May;29(5):1177-85. doi: 10.1038/leu.2014.330. Epub 2014 Nov 27.

PMID:
25428260
19.

Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK.

Krysov S, Steele AJ, Coelho V, Linley A, Sanchez Hidalgo M, Carter M, Potter KN, Kennedy B, Duncombe AS, Ashton-Key M, Forconi F, Stevenson FK, Packham G.

Blood. 2014 Nov 13;124(20):3101-9. doi: 10.1182/blood-2014-04-567198. Epub 2014 Aug 28.

20.

Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98).

Lee CS, Ashton-Key M, Cogliatti S, Rondeau S, Schmitz SF, Ghielmini M, Cragg MS, Johnson P.

Br J Haematol. 2015 Jan;168(1):145-8. doi: 10.1111/bjh.13071. Epub 2014 Aug 21. No abstract available.

PMID:
25142001
21.

Time to publication for NIHR HTA programme-funded research: a cohort study.

Chinnery F, Young A, Goodman J, Ashton-Key M, Milne R.

BMJ Open. 2013 Nov 27;3(11):e004121. doi: 10.1136/bmjopen-2013-004121.

22.

Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells.

Krysov S, Dias S, Paterson A, Mockridge CI, Potter KN, Smith KA, Ashton-Key M, Stevenson FK, Packham G.

Blood. 2012 Jan 5;119(1):170-9. doi: 10.1182/blood-2011-07-370403. Epub 2011 Nov 15.

PMID:
22086413
23.

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HT, Beers SA, French RR, Cox KL, Davies AJ, Potter KN, Mockridge CI, Oscier DG, Johnson PW, Cragg MS, Glennie MJ.

Blood. 2011 Sep 1;118(9):2530-40. doi: 10.1182/blood-2011-01-330357. Epub 2011 Jul 18.

PMID:
21768293
24.

Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development.

McCann KJ, Ashton-Key M, Smith K, Stevenson FK, Ottensmeier CH.

Blood. 2009 May 7;113(19):4677-80. doi: 10.1182/blood-2008-09-179366. Epub 2008 Dec 18.

PMID:
19096008
25.

Intestinal strictures: a new complication of treatment for primary gastrointestinal diffuse large B-cell lymphoma.

Kerr JP, Turner M, Ashton-Key M, Mead GM, Johnson PW.

Br J Haematol. 2008 Mar;140(6):712-4. doi: 10.1111/j.1365-2141.2007.06950.x. Epub 2008 Jan 22. No abstract available.

PMID:
18218049
26.

Setting the future policy agenda for health technology assessment: a specialty mapping approach.

Shepherd J, Briggs J, Payne L, Packer C, Kerridge L, Ashton-Key M.

Int J Technol Assess Health Care. 2007 Fall;23(4):405-13.

PMID:
17937827
28.

Diagnostic value and cost-effectiveness of bronchial brushings in the diagnosis of bronchial malignancy.

Youd E, Ashton-Key M.

Cytopathology. 2005 Oct;16(5):263-4; author reply 264. No abstract available.

PMID:
16181316
30.
31.

The first reported sudden fatality from pulmonary artery compression by a thymic cyst.

Hart SR, Ashton-Key M.

Hosp Med. 2001 Oct;62(10):644-5. No abstract available.

PMID:
11688131
32.

Evaluation of fine-needle aspiration cytology for renal masses.

Brierly RD, Thomas PJ, Harrison NW, Fletcher MS, Nawrocki JD, Ashton-Key M.

BJU Int. 2000 Jan;85(1):14-8.

33.

Alcohol consumption and mortality. Underestimates of consumption are possible.

Ashton-Key M, Ashton-Key M.

BMJ. 1999 Nov 6;319(7219):1267; author reply 1267-8. No abstract available.

34.

Aggressive NK cell lymphoma preceded by a ten year history of neutropenia associated with large granular lymphocyte lymphocytosis.

De Lord C, Mercieca J, Ashton-Key M, Singh L, Ryley S, Isaacson P, Catovsky D.

Leuk Lymphoma. 1998 Oct;31(3-4):417-21.

PMID:
9869207
35.

Pitfalls in the diagnosis of papillary carcinoma of the thyroid.

Kulacoglu S, Ashton-Key M, Buley I.

Cytopathology. 1998 Jun;9(3):193-200. Review. No abstract available.

PMID:
9638381
36.

Langerhans cell histiocytosis associated with papillary carcinoma of the thyroid.

Lindley R, Hoile R, Schofield J, Ashton-Key M.

Histopathology. 1998 Feb;32(2):180. No abstract available.

PMID:
9543676
37.

Molecular analysis of T-cell clonality in ulcerative jejunitis and enteropathy-associated T-cell lymphoma.

Ashton-Key M, Diss TC, Pan L, Du MQ, Isaacson PG.

Am J Pathol. 1997 Aug;151(2):493-8.

38.

The value of the polymerase chain reaction in the diagnosis of cutaneous T-cell infiltrates.

Ashton-Key M, Diss TC, Du MQ, Kirkham N, Wotherspoon A, Isaacson PG.

Am J Surg Pathol. 1997 Jul;21(7):743-7.

PMID:
9236829
39.

CD45 immunostaining in T-cell-rich B-cell lymphoma and lymphocyte predominance Hodgkin's disease.

Ashton-Key M, Isaacson PG.

J Pathol. 1997 Apr;181(4):462-3. No abstract available.

PMID:
9196447
40.

Immunoglobulin light chain staining in paraffin-embedded tissue using a heat mediated epitope retrieval method.

Ashton-Key M, Jessup E, Isaacson PG.

Histopathology. 1996 Dec;29(6):525-31.

PMID:
8971559
41.

HLA antigen expression in enteropathy associated T cell lymphoma.

Ashton-Key M, Singh N, Pan LX, Smith ME.

J Clin Pathol. 1996 Jul;49(7):545-8.

42.

Phenotype of Hodgkin and Reed-Sternberg cells.

Isaacson PG, Ashton-Key M.

Lancet. 1996 Feb 17;347(8999):481. No abstract available.

PMID:
8618524
43.

Detection of Helicobacter pylori in gastric biopsy and resection specimens.

Ashton-Key M, Diss TC, Isaacson PG.

J Clin Pathol. 1996 Feb;49(2):107-11.

44.

Cadherins in reactive lymph nodes and lymphomas: high expression in anaplastic large cell lymphomas.

Ashton-Key M, Cowley GP, Smith ME.

Histopathology. 1996 Jan;28(1):55-9.

PMID:
8838121
45.
46.

Follicular Hodgkin's disease.

Ashton-Key M, Thorpe PA, Allen JP, Isaacson PG.

Am J Surg Pathol. 1995 Nov;19(11):1294-9.

PMID:
7573692
47.

Clonality analysis of B-cell lymphomas.

Diss TC, Ashton-Key M, Pan LX, Isaacson PG.

Hum Pathol. 1995 Sep;26(9):1046. No abstract available.

PMID:
7672790
48.

Heterogeneity of bcl-2 expression in MALT lymphoma.

Ashton-Key M, Biddolph SC, Stein H, Gatter KC, Mason DY.

Histopathology. 1995 Jan;26(1):75-8.

PMID:
7713486
49.

Pilomatrixoma of the external auditory meatus.

Vinayak BC, Cox GJ, Ashton-Key M.

J Laryngol Otol. 1993 Apr;107(4):333-4.

PMID:
8320521
50.

False-negative temporal artery biopsy.

Ashton-Key MR, Gallagher PJ.

Am J Surg Pathol. 1992 Jun;16(6):634-5. No abstract available.

PMID:
1599042

Supplemental Content

Loading ...
Support Center